List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1945979/publications.pdf Version: 2024-02-01



DHILIDD F RADTKO

#	Article	IF	CITATIONS
1	Severe tricuspid regurgitation: prognostic role of right heart remodelling and pulmonary hypertension. European Heart Journal Cardiovascular Imaging, 2022, 23, 246-254.	1.2	12
2	Access site complications of postcardiotomy extracorporeal life support. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1546-1558.e8.	0.8	9
3	Circulating dipeptidyl peptidase (cDPP3)—A marker for endâ€stage heart failure?. Journal of Internal Medicine, 2022, 291, 886-890.	6.0	2
4	Fate of patients weaned from post-cardiotomy extracorporeal life support. European Journal of Cardio-thoracic Surgery, 2022, 61, 1178-1185.	1.4	9
5	Tricuspid regurgitation: recent advances in understanding pathophysiology, severity grading and outcome. European Heart Journal Cardiovascular Imaging, 2022, 23, 913-929.	1.2	73
6	Transcatheter Versus Surgical Valve Repair in Patients with Severe Mitral Regurgitation. Journal of Personalized Medicine, 2022, 12, 90.	2.5	2
7	Neutrophil Activation/Maturation Markers in Chronic Heart Failure with Reduced Ejection Fraction. Diagnostics, 2022, 12, 444.	2.6	8
8	Guideline directed <i>medical</i> therapy and reduction of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2022, 23, 755-764.	1.2	9
9	Cerebral Protection in TAVR—Can We Do Without? A Real-World All-Comer Intention-to-Treat Study—Impact on Stroke Rate, Length of Hospital Stay, and Twelve-Month Mortality. Journal of Personalized Medicine, 2022, 12, 320.	2.5	5
10	Malnutrition outweighs the effect of the obesity paradox. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 1477-1486.	7.3	12
11	6-Month Outcomes of the TricValveÂSystem in Patients With Tricuspid Regurgitation. JACC: Cardiovascular Interventions, 2022, 15, 1366-1377.	2.9	51
12	Comprehensive myocardial characterization using cardiac magnetic resonance associates with outcomes in low gradient severe aortic stenosis. European Heart Journal Cardiovascular Imaging, 2022, 24, 46-58.	1.2	9
13	Adaptive development of concomitant secondary mitral and tricuspid regurgitation after transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1045-1053.	1.2	14
14	Increased concentrations of bioactive adrenomedullin subsequently to angiotensinâ&receptor/neprilysinâ&inhibitor treatment in chronic systolic heart failure. British Journal of Clinical Pharmacology, 2021, 87, 916-924.	2.4	13
15	Gastric regurgitation predicts neurological outcome in out-of-hospital cardiac arrest survivors. European Journal of Internal Medicine, 2021, 83, 54-57.	2.2	4
16	A machine learning algorithm supports ultrasound-naÃ <sup>-</sup> ve novices in the acquisition of diagnostic echocardiography loops and provides accurate estimation of LVEF. International Journal of Cardiovascular Imaging, 2021, 37, 577-586.	1.5	37
17	Natural Course of Nonsevere Secondary Tricuspid Regurgitation. Journal of the American Society of Echocardiography, 2021, 34, 13-19.	2.8	19
18	The Paradox of Secondary Mitral Regurgitation. JACC: Cardiovascular Imaging, 2021, 14, 740-741.	5.3	5

#	Article	IF	CITATIONS
19	Secondary mitral regurgitation—Insights from microRNA assessment. European Journal of Clinical Investigation, 2021, 51, e13381.	3.4	4
20	Death is associated to the type of drug-eluting stent in patients with left ventricular dysfunction and elevated natriuretic peptide levels. Scientific Reports, 2021, 11, 2443.	3.3	0
21	Novel Identified Circular Transcript of RCAN2, circ-RCAN2, Shows Deviated Expression Pattern in Pig Reperfused Infarcted Myocardium and Hypoxic Porcine Cardiac Progenitor Cells In Vitro. International Journal of Molecular Sciences, 2021, 22, 1390.	4.1	4
22	Performance of the recommended ESC/EASD cardiovascular risk stratification model in comparison to SCORE and NT-proBNP as a single biomarker for risk prediction in type 2 diabetes mellitus. Cardiovascular Diabetology, 2021, 20, 34.	6.8	20
23	Pacemaker lead-associated tricuspid regurgitation in patients with or without pre-existing right ventricular dilatation. Clinical Research in Cardiology, 2021, 110, 884-894.	3.3	15
24	Fluid overload in patients undergoing TAVR: what we can learn from the nephrologists. ESC Heart Failure, 2021, 8, 1408-1416.	3.1	7
25	Transcatheter treatment by valve-in-valve and valve-in-ring implantation for prosthetic tricuspid valve dysfunction. Wiener Klinische Wochenschrift, 2021, 133, 780-785.	1.9	4
26	Neprilysin inhibition does not alter dynamic of proenkephalinâ€A 119â€159 and proâ€substance P in heart failure. ESC Heart Failure, 2021, 8, 2016-2024.	3.1	3
27	Myocardial Angiotensin Metabolism in End-Stage HeartÂFailure. Journal of the American College of Cardiology, 2021, 77, 1731-1743.	2.8	18
28	Usefulness of the B-Type Natriuretic Peptides in Low Ejection Fraction, Low-Flow, Low-Gradient Aortic Stenosis Results from the TOPAS Multicenter Prospective Cohort Study. Structural Heart, 2021, 5, 319-327.	0.6	2
29	Gender differences in the provision of intensive care: a Bayesian approach. Intensive Care Medicine, 2021, 47, 577-587.	8.2	36
30	ST-Segment Elevation Myocardial Infarction Following Transcatheter Aortic Valve Replacement. Journal of the American College of Cardiology, 2021, 77, 2187-2199.	2.8	35
31	Prognostic Value of Echocardiographic Right Ventricular Function Parameters in the Presence of Severe Tricuspid Regurgitation. Journal of Clinical Medicine, 2021, 10, 2266.	2.4	3
32	Percutaneous bail-out in severe acute mitral regurgitation: when surgery is not an option. European Heart Journal - Case Reports, 2021, 5, ytab207.	0.6	0
33	Impact of Venoarterial Extracorporeal Membrane Oxygenation on Alkaline Phosphatase Metabolism after Cardiac Surgery. Biomolecules, 2021, 11, 748.	4.0	1
34	Burden, treatment use, and outcome of secondary mitral regurgitation across the spectrum of heart failure: observational cohort study. BMJ, The, 2021, 373, n1421.	6.0	32
35	Impact of sex on the management and outcome of aortic stenosis patients: a female aortic valve stenosis paradox, and a call for personalized treatments?. European Heart Journal, 2021, 42, 2692-2694.	2.2	5
36	Principal Morphomic and FunctionalÂComponents of Secondary MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2021, 14, 2288-2300.	5.3	26

#	Article	IF	CITATIONS
37	Clinical Impact of Pre-Procedural Percutaneous Coronary Intervention in Low- and Intermediate-Risk Transcatheter Aortic Valve Replacement Recipients. Journal of Personalized Medicine, 2021, 11, 633.	2.5	1
38	Durable Reduction of Mitral Regurgitation After 2 Years. JACC: Cardiovascular Interventions, 2021, 14, 1549-1550.	2.9	0
39	Catalase Predicts In-Hospital Mortality after Out-of-Hospital Cardiac Arrest. Journal of Clinical Medicine, 2021, 10, 3906.	2.4	1
40	Mitral regurgitation tips the scales in acute or worsening heart failure. European Journal of Heart Failure, 2021, 23, 1763-1764.	7.1	0
41	Heart Failure with Preserved Ejection Fraction after Leftâ€sided Valve Surgery: Prevalent and Relevant. European Journal of Heart Failure, 2021, , .	7.1	5
42	Secondary tricuspid regurgitation: neglected no more!. European Heart Journal Cardiovascular Imaging, 2021, 22, 166-167.	1.2	1
43	Inflammation-Based Scores as a Common Tool for Prognostic Assessment in Heart Failure or Cancer. Frontiers in Cardiovascular Medicine, 2021, 8, 725903.	2.4	12
44	Relevance of Neutrophil Neprilysin in Heart Failure. Cells, 2021, 10, 2922.	4.1	5
45	Right ventricular function and outcome in patients undergoing transcatheter aortic valve replacement. European Heart Journal Cardiovascular Imaging, 2021, 22, 1295-1303.	1.2	12
46	Transcatheter TricValve implantation for the treatment of severe tricuspid regurgitation. European Heart Journal Cardiovascular Imaging, 2021, 22, e92-e92.	1.2	6
47	Clinical Value of Stress Transaortic Flow Rate During Dobutamine Echocardiography in Reduced Left Ventricular Ejection Fraction, Low-Gradient Aortic Stenosis: A Multicenter Study. Circulation: Cardiovascular Imaging, 2021, 14, e012809.	2.6	5
48	A Real World 10-Year Experience With Vascular Closure Devices and Large-Bore Access in Patients Undergoing Transfemoral Transcatheter Aortic Valve Implantation. Frontiers in Cardiovascular Medicine, 2021, 8, 791693.	2.4	3
49	N-terminal pro-brain natriuretic peptide and high-sensitivity troponin T exhibit additive prognostic value for the outcome of critically ill patients. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 496-503.	1.0	4
50	Determinants of Bioprosthetic AorticÂValve Degeneration. JACC: Cardiovascular Imaging, 2020, 13, 345-353.	5.3	27
51	Transcatheter versus surgical aortic valve replacement in low-risk patients: a meta-analysis of randomized trials. Clinical Research in Cardiology, 2020, 109, 761-775.	3.3	9
52	Large Animal Models of Cell-Free Cardiac Regeneration. Biomolecules, 2020, 10, 1392.	4.0	15
53	Evolution of outcome and complications in TAVR: a meta-analysis of observational and randomized studies. Scientific Reports, 2020, 10, 15568.	3.3	60
54	An Integrated Imaging and Circulating Biomarker Approach for Secondary Tricuspid Regurgitation. Journal of Personalized Medicine, 2020, 10, 233.	2.5	1

#	Article	IF	CITATIONS
55	Prescription Bias in the Treatment of Chronic Systolic Heart Failure. Annals of Internal Medicine, 2020, 172, 70.	3.9	2
56	Heart Failure With Reduced Ejection Fraction Is Characterized by Systemic NEP Downregulation. JACC Basic To Translational Science, 2020, 5, 715-726.	4.1	9
57	Interdependence of VA-ECMO output, pulmonary congestion and outcome after cardiac surgery. European Journal of Internal Medicine, 2020, 81, 67-70.	2.2	8
58	Circular RNAs in Cardiac Regeneration: Cardiac Cell Proliferation, Differentiation, Survival, and Reprogramming. Frontiers in Physiology, 2020, 11, 580465.	2.8	13
59	Current Insights Into Secondary Mitral Regurgitation—Workup and Management. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 1.	0.9	0
60	Comparative Effect of MSC Secretome to MSC Co-culture on Cardiomyocyte Gene Expression Under Hypoxic Conditions in vitro. Frontiers in Bioengineering and Biotechnology, 2020, 8, 502213.	4.1	5
61	Detection of atrial shunt lesions with aÂsingle echocardiographic parameter. Wiener Klinische Wochenschrift, 2020, 132, 295-300.	1.9	4
62	Simultaneous transcatheter mitral valve-in-mitral annular calcification and aortic valve-in-valve implantation: benefits of advanced multimodality imaging. European Heart Journal Cardiovascular Imaging, 2020, 21, 1433-1433.	1.2	0
63	An Extended Duration of the Pre-Operative Hospitalization is Associated with an Increased Risk of Healthcare-Associated Infections after Cardiac Surgery. Scientific Reports, 2020, 10, 8006.	3.3	10
64	Tricuspid regurgitation secondary to heart failure: more pieces to solve the puzzle. European Journal of Heart Failure, 2020, 22, 1814-1816.	7.1	1
65	Predicting the presence of coronary artery disease by transesophageal echocardiography. Wiener Klinische Wochenschrift, 2020, 132, 708-715.	1.9	2
66	Impact of treatment strategies on long-term outcome of CTO patients. European Journal of Internal Medicine, 2020, 77, 97-104.	2.2	7
67	Increased resting heart rate and prognosis in treatmentâ€naÃ⁻ve unselected cancer patients: results from a prospective observational study. European Journal of Heart Failure, 2020, 22, 1230-1238.	7.1	23
68	Pulmonary artery to ascending aorta ratio by echocardiography: A strong predictor for presence and severity of pulmonary hypertension. PLoS ONE, 2020, 15, e0235716.	2.5	12
69	Recommendations for extracorporeal membrane oxygenation (ECMO) in COVID-19 patients. Wiener Klinische Wochenschrift, 2020, 132, 671-676.	1.9	9
70	The inflammationâ€based modified Glasgow prognostic score is associated with survival in stable heart failure patients. ESC Heart Failure, 2020, 7, 654-662.	3.1	23
71	Lightâ€chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. European Journal of Heart Failure, 2020, 22, 1852-1862.	7.1	82
72	Interventional treatment of tricuspid regurgitation. Wiener Klinische Wochenschrift, 2020, 132, 57-60.	1.9	1

#	Article	IF	CITATIONS
73	Proteomics-Enriched Prediction Model for Poor Neurologic Outcome in Cardiac Arrest Survivors*. Critical Care Medicine, 2020, 48, 167-175.	0.9	16
74	Systematic Evaluation of Systemic Right Ventricular Function. Journal of Clinical Medicine, 2020, 9, 107.	2.4	5
75	Secondary valve regurgitation in patients with heart failure with preserved ejection fraction, heart failure with mid-range ejection fraction, and heart failure with reduced ejection fraction. European Heart Journal, 2020, 41, 2799-2810.	2.2	45
76	Atherosclerotic plaque detected by transesophageal echocardiography is an independent predictor for all-cause mortality. International Journal of Cardiovascular Imaging, 2020, 36, 1437-1443.	1.5	4
77	Left Main Coronary Artery Disease and Outcomes after Percutaneous Coronary Intervention for Chronic Total Occlusions. Journal of Clinical Medicine, 2020, 9, 938.	2.4	3
78	Intestinal Fatty Acid Binding Protein is Associated With Mortality in Patients With Acute Heart Failure or Cardiogenic Shock. Shock, 2019, 51, 410-415.	2.1	17
79	Blood urea nitrogen has additive value beyond estimated glomerular filtration rate for prediction of long-term mortality in patients with acute myocardial infarction. European Journal of Internal Medicine, 2019, 59, 84-90.	2.2	28
80	Cardiac arrest as an age-dependent prognosticator for long-term mortality after acute myocardial infarction: the potential impact of infarction size. European Heart Journal: Acute Cardiovascular Care, 2019, 8, 153-160.	1.0	4
81	Papillary Muscle Dyssynchrony-Mediated Functional Mitral Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1728-1737.	5.3	21
82	Global regurgitant volume: approaching the critical mass in valvular-driven heart failure. European Heart Journal Cardiovascular Imaging, 2019, 21, 168-174.	1.2	5
83	Carotid ultrasound investigation as a prognostic tool for patients with diabetes mellitus. Cardiovascular Diabetology, 2019, 18, 90.	6.8	16
84	Disproportionate Functional MitralÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 2088-2090.	5.3	32
85	Phenotyping progression of secondary mitral regurgitation in chronic systolic heart failure. European Journal of Clinical Investigation, 2019, 49, e13159.	3.4	10
86	High N-Terminal proB-Type Natriuretic Peptide Indicates Elevated Risk of Death after Percutaneous Coronary Intervention Compared to Coronary Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. Journal of Clinical Medicine, 2019, 8, 898.	2.4	6
87	A Contemporary Definition of Periprocedural Myocardial Injury After Percutaneous Coronary Intervention of Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2019, 12, 1915-1923.	2.9	22
88	GDFâ€15 in solid vs nonâ€solid treatmentâ€naÃ⁻ve malignancies. European Journal of Clinical Investigation, 2019, 49, e13168.	3.4	10
89	Reply. Journal of the American College of Cardiology, 2019, 74, 1845-1847.	2.8	3
90	Echocardiographic evaluation of left ventricular filling pressures in patients with pulmonary hypertension. International Journal of Cardiovascular Imaging, 2019, 35, 861-868.	1.5	6

#	Article	IF	CITATIONS
91	Visual assessment of right ventricular function by echocardiography: how good are we?. International Journal of Cardiovascular Imaging, 2019, 35, 2001-2008.	1.5	23
92	A Unifying Concept for the QuantitativeÂAssessment of SecondaryÂMitral Regurgitation. Journal of the American College of Cardiology, 2019, 73, 2506-2517.	2.8	86
93	Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure. European Journal of Heart Failure, 2019, 21, 537-539.	7.1	4
94	The circulating form of neprilysin is not a general biomarker for overall survival in treatment-naÃ <sup>-</sup> ve cancer patients. Scientific Reports, 2019, 9, 2554.	3.3	18
95	Discriminatory power of scoring systems for outcome prediction in patients with extracorporeal membrane oxygenation following cardiovascular surgeryâ€. European Journal of Cardio-thoracic Surgery, 2019, 56, 534-540.	1.4	12
96	Aortic stenosis is an independent predictor for outcome in patients with in-hospital cardiac arrest. Resuscitation, 2019, 137, 156-160.	3.0	4
97	Echocardiographic assessment of right ventricular function: current clinical practice. International Journal of Cardiovascular Imaging, 2019, 35, 49-56.	1.5	53
98	Syncope. JACC: Cardiovascular Imaging, 2019, 12, 225-232.	5.3	22
99	Diagnostic and Prognostic Utility of Cardiac Magnetic Resonance Imaging inÂAortic Regurgitation. JACC: Cardiovascular Imaging, 2019, 12, 1474-1483.	5.3	59
100	Natural History of FunctionalÂTricuspidÂRegurgitation. JACC: Cardiovascular Imaging, 2019, 12, 389-397.	5.3	102
101	Natural history of bivalvular functional regurgitation. European Heart Journal Cardiovascular Imaging, 2019, 20, 565-573.	1.2	9
102	Acute HIV Infection Results in Subclinical Inflammatory Cardiomyopathy. Journal of Infectious Diseases, 2018, 218, 466-470.	4.0	12
103	Relationship Between Proximal Aorta Morphology and Progression Rate of Aortic Stenosis. Journal of the American Society of Echocardiography, 2018, 31, 561-569.e1.	2.8	7
104	Duration of extracorporeal membrane oxygenation support and survival in cardiovascular surgery patients. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2471-2476.	0.8	39
105	Preclinical Studies of Stem Cell Therapy for Heart Disease. Circulation Research, 2018, 122, 1006-1020.	4.5	104
106	Evolution of secondary mitral regurgitation. European Heart Journal Cardiovascular Imaging, 2018, 19, 622-629.	1.2	40
107	Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. European Heart Journal, 2018, 39, 39-46.	2.2	261
108	Normal values for Doppler echocardiographic assessment of prosthetic valve function after transcatheter aortic valve replacement: a systematic review and meta-analysis. European Heart Journal Cardiovascular Imaging, 2018, 19, 361-368.	1.2	10

#	Article	IF	CITATIONS
109	Low- and High-renin Heart Failure Phenotypes with Clinical Implications. Clinical Chemistry, 2018, 64, 597-608.	3.2	52
110	Transcatheter aortic valve replacement (TAVR) leads to an increase in the subendocardial viability ratio assessed by pulse wave analysis. PLoS ONE, 2018, 13, e0207537.	2.5	14
111	Quantitative Definition of Severe Functional Mitral Regurgitation. Journal of the American College of Cardiology, 2018, 72, 2934-2935.	2.8	15
112	De-Ritis Ratio Improves Long-Term Risk Prediction after Acute Myocardial Infarction. Journal of Clinical Medicine, 2018, 7, 474.	2.4	41
113	CD4+CD28null T Lymphocytes are Associated with the Development of Atrial Fibrillation after Elective Cardiac Surgery. Scientific Reports, 2018, 8, 9624.	3.3	19
114	Lipid profile and longâ€ŧerm outcome in premature myocardial infarction. European Journal of Clinical Investigation, 2018, 48, e13008.	3.4	18
115	Polyunsaturated fatty acids supplementation impairs antiâ€oxidant highâ€density lipoprotein function in heart failure. European Journal of Clinical Investigation, 2018, 48, e12998.	3.4	9
116	Research update for articles published in <scp>EJCI</scp> in 2016. European Journal of Clinical Investigation, 2018, 48, e13016.	3.4	0
117	Immunomodulatory treatment for lymphocytic myocarditis—a systematic review and meta-analysis. Heart Failure Reviews, 2018, 23, 573-581.	3.9	22
118	Clusterin/apolipoprotein J is independently associated with survival in patients with chronic heart failure. Journal of Clinical Lipidology, 2017, 11, 178-184.	1.5	19
119	Sequential activation of different pathway networks in ischemia-affected and non-affected myocardium, inducing intrinsic remote conditioning to prevent left ventricular remodeling. Scientific Reports, 2017, 7, 43958.	3.3	33
120	Long-term outcome and risk assessment in premature acute myocardial infarction: A 10-year follow-up study. International Journal of Cardiology, 2017, 240, 37-42.	1.7	15
121	Echo-Doppler estimation of left ventricular filling pressure: results of the multicentre EACVI Euro-Filling study. European Heart Journal Cardiovascular Imaging, 2017, 18, 961-968.	1.2	253
122	Large vessel vasculitis in Behçet's disease. European Heart Journal Cardiovascular Imaging, 2017, 18, 724-724.	1.2	1
123	Soluble Urokinase-Type Plasminogen Activator Receptor Improves RiskÂPrediction in Patients With ChronicÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 268-277.	4.1	37
124	Research update for articles published in EJCI in 2015. European Journal of Clinical Investigation, 2017, 47, 775-788.	3.4	0
125	Acute Leukemia is Associated with Cardiac Alterations before Chemotherapy. Journal of the American Society of Echocardiography, 2017, 30, 1111-1118.	2.8	27
126	Impact of Right Ventricular Performance in Patients Undergoing Extracorporeal Membrane Oxygenation Following Cardiac Surgery. Journal of the American Heart Association, 2017, 6, .	3.7	13

#	Article	IF	CITATIONS
127	Multi-view approach for the diagnosis of pulmonary hypertension using transthoracic echocardiography. International Journal of Cardiovascular Imaging, 2017, 34, 695-700.	1.5	13
128	The aureole sign: a rare echocardiographic artefact. European Heart Journal Cardiovascular Imaging, 2017, 18, 722-722.	1.2	0
129	Refining Long-Term Prediction of Cardiovascular Risk in Diabetes – The VILDIA Score. Scientific Reports, 2017, 7, 4700.	3.3	11
130	Long-term outcome and risk prediction in patients suffering acute myocardial infarction complicated by post-infarction cardiac rupture. International Journal of Cardiology, 2017, 227, 399-403.	1.7	28
131	Effect of Losartan on Mitral Valve Changes After Myocardial Infarction. Journal of the American College of Cardiology, 2017, 70, 1232-1244.	2.8	97
132	Global position paper on cardiovascular regenerative medicine. European Heart Journal, 2017, 38, 2532-2546.	2.2	133
133	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. Journal of Translational Medicine, 2017, 15, 202.	4.4	33
134	Subclinical involvement of the liver is associated with prognosis in treatment naÃ <sup>-</sup> ve cancer patients. Oncotarget, 2017, 8, 81250-81260.	1.8	15
135	Intrinsic remote conditioning of the myocardium as a comprehensive cardiac response to ischemia and reperfusion. Oncotarget, 2017, 8, 67227-67240.	1.8	5
136	Short structured feedback training is equivalent to a mechanical feedback device in two-rescuer BLS: a randomised simulation study. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2016, 24, 70.	2.6	19
137	Soluble galectinâ€3 is associated with premature myocardial infarction. European Journal of Clinical Investigation, 2016, 46, 386-391.	3.4	23
138	Cardiac arrest does not affect survival in post-operative cardiovascular surgery patients undergoing extracorporeal membrane oxygenation. Resuscitation, 2016, 104, 24-27.	3.0	22
139	Molecular Imaging of Angiogenesis in Cardiac Regeneration. Current Cardiovascular Imaging Reports, 2016, 9, 27.	0.6	17
140	Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 89-93.	7.1	43
141	Genderâ€related differences in elderly patients with myocardial infarction in a European Centre. European Journal of Clinical Investigation, 2016, 46, 60-69.	3.4	7
142	The power of ultrasound: treating secondary MR with sound waves. European Heart Journal Cardiovascular Imaging, 2016, 17, 1108-1109.	1.2	0
143	Anticipating the Vicious Circle of Postinfarction Mitral Regurgitation. Circulation: Cardiovascular Imaging, 2016, 9, .	2.6	2
144	Combined Effects of Inflammatory Status and Carotid Atherosclerosis. Stroke, 2016, 47, 2952-2958.	2.0	17

#	Article	IF	CITATIONS
145	Myocardial Infarction Alters Adaptation ofÂthe Tethered Mitral Valve. Journal of the American College of Cardiology, 2016, 67, 275-287.	2.8	93
146	3D Ultrasound: seeing is understanding—from imaging to pathophysiology to developing therapies in secondary MR. European Heart Journal Cardiovascular Imaging, 2016, 17, 510-511.	1.2	0
147	Liver function predicts survival in patients undergoing extracorporeal membrane oxygenation following cardiovascular surgery. Critical Care, 2016, 20, 57.	5.8	46
148	Sphingosine-1-Phosphate Receptor Agonist Fingolimod Increases Myocardial Salvage and Decreases Adverse Postinfarction Left Ventricular Remodeling in a Porcine Model of Ischemia/Reperfusion. Circulation, 2016, 133, 954-966.	1.6	155
149	Evaluation of six different airway devices regarding regurgitation and pulmonary aspiration during cardio-pulmonary resuscitation (CPR) – A human cadaver pilot study. Resuscitation, 2016, 102, 70-74.	3.0	51
150	Impaired High-Density Lipoprotein Anti-Oxidant Function Predicts Poor Outcome in Critically III Patients. PLoS ONE, 2016, 11, e0151706.	2.5	8
151	Impaired antioxidant HDL function is associated with premature myocardial infarction. European Journal of Clinical Investigation, 2015, 45, 731-738.	3.4	21
152	Research update for articles published in <scp>EJCI</scp> in 2013. European Journal of Clinical Investigation, 2015, 45, 1005-1016.	3.4	1
153	The impact of selectins on mortality in stable carotid atherosclerosis. Thrombosis and Haemostasis, 2015, 114, 632-638.	3.4	17
154	Association of Small Dense LDL Serum Levels and Circulating Monocyte Subsets in Stable Coronary Artery Disease. PLoS ONE, 2015, 10, e0123367.	2.5	33
155	Butyrylcholinesterase Predicts Cardiac Mortality in Young Patients with Acute Coronary Syndrome. PLoS ONE, 2015, 10, e0123948.	2.5	9
156	The C-MAC videolaryngoscope compared with conventional laryngoscopy for rapid sequence intubation at the emergency department: study protocol. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 2015, 23, 38.	2.6	5
157	Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). Journal of Clinical Lipidology, 2015, 9, 533-541.	1.5	37
158	Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. Journal of Clinical Lipidology, 2015, 9, 801-806.e1.	1.5	45
159	Von Willebrand Factor Improves Risk Prediction in Addition to N-Terminal Pro–B-type Natriuretic Peptide in Patients Referred to Coronary Angiography and Signs and Symptoms of Heart Failure and Preserved Ejection Fraction. Circulation: Heart Failure, 2015, 8, 25-32.	3.9	25
160	Multimodality imaging of a primary cardiac diffuse large B-cell lymphoma:. European Heart Journal Cardiovascular Imaging, 2015, 16, 909-909.	1.2	4
161	Dark chocolate and vascular function in patients with peripheral artery disease: A randomized, controlled cross-over trial. Clinical Hemorheology and Microcirculation, 2015, 59, 145-153.	1.7	12
162	Variation of lipoprotein(a) plasma levels after premature myocardial infarction. International Journal of Cardiology, 2015, 186, 5-6.	1.7	4

#	Article	IF	CITATIONS
163	Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart, 2015, 101, 1874-1880.	2.9	181
164	Fibroblast Growth Factor 23 Is an Independent and Specific Predictor of Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Circulation: Heart Failure, 2015, 8, 1059-1067.	3.9	42
165	Outcome in Heart Failure with Preserved Ejection Fraction: The Role of Myocardial Structure and Right Ventricular Performance. PLoS ONE, 2015, 10, e0134479.	2.5	26
166	Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis, 2014, 237, 589-596.	0.8	38
167	Three-Dimensional Principal Strain Analysis forÂCharacterizing Subclinical Changes in Left Ventricular Function. Journal of the American Society of Echocardiography, 2014, 27, 1041-1050.e1.	2.8	68
168	Independent or synergistic relationship of proteinuria and glomerular filtration rate on patient and renal survival in patients with glomerulonephritis?. Journal of Nephrology, 2014, 27, 643-651.	2.0	0
169	Predictive power of the fractalkine receptor CX3CR1 on CD4 T cells in patients with chronic heart failure. International Journal of Cardiology, 2014, 171, 96-97.	1.7	9
170	Evaluation of advanced airway management in absolutely inexperienced hands. European Journal of Emergency Medicine, 2013, 20, 310-314.	1.1	28
171	Platelet count predicts cardiovascular mortality in very elderly patients with myocardial infarction. European Journal of Clinical Investigation, 2013, 43, 332-340.	3.4	14
172	Routinely available biomarkers improve prediction of long-term mortality in stable coronary artery disease: the Vienna and Ludwigshafen Coronary Artery Disease (VILCAD) risk score. European Heart Journal, 2012, 33, 2282-2289.	2.2	55
173	Butyrylcholinesterase Activity Predicts Long-Term Survival in Patients with Coronary Artery Disease. Clinical Chemistry, 2012, 58, 1055-1058.	3.2	31
174	Premature myocardial infarction is associated with low serum levels of Wnt-1. Atherosclerosis, 2012, 222, 251-256.	0.8	42
175	Usefulness of Hemoglobin Level to Predict Long-Term Mortality in Patients With Asymptomatic Carotid Narrowing by Ultrasonography. American Journal of Cardiology, 2012, 110, 1699-1703.	1.6	3
176	Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (â‰≇€ƒ40 years of age). European Journal of Clinical Investigation, 2012, 42, 631-636.	3.4	59

The effect of p22-PHOX (CYBA) polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{2}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  and  $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on polymorphisms on premature coronary artery disease ( $a^{3}$  by the polymorphisms on polymorphisms on